dysgeusia/рак дојке

Веза се чува у привремену меморију

Изаберите тип сортирања

Страна 1 од 24 резултати

Hypoglossal acupuncture for acute chemotherapy-induced dysgeusia in patients with breast cancer: study protocol of a randomized, sham-controlled trial.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Distortion of taste sensations is a common chemotherapy-induced side effect; however, treatment evidence is limited. Pilot data indicated that acupuncture might be able to improve symptoms of dysgeusia. Thus, the aim of this study is to investigate the effects and side effects of

Awareness of dysgeusia and gustatory tests in patients undergoing chemotherapy for breast cancer.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE We analyzed the prevalence of gustatory test abnormalities in breast cancer (BC) patients undergoing chemotherapy. METHODS We enrolled 43 BC patients undergoing chemotherapy and 38 BC patients who had never undergone chemotherapy (control group). Two gustatory tests were conducted: an

Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

The present study was a proof-of-concept study to provide an initial indication of the efficacy and safety of imaging malignant breast tumors using (99m)Tc-NC100692. The agent is a small peptide with high affinity for integrin receptors that are upregulated and expressed preferentially on

Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

BACKGROUND Evidence on adjuvant chemotherapy in older women with breast cancer is poor. We tested whether weekly docetaxel is more effective than standard chemotherapy. METHODS We carried out a multicenter, randomized phase III study. Women aged 65-79, operated for breast cancer, with average to

Comparison of Doctors' and Breast Cancer Patients' Perceptions of Docetaxel, Epirubicin, and Cyclophosphamide (TEC) Toxicity.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

In Spain, around 26,000 cases of breast cancer are diagnosed each year, representing nearly 30% of all cancers in women. The aim this study was to compare the perceptions of nonhematologic toxicities after administration of a docetaxel, epirubicin, and cyclophosphamide (TEC) regimen between breast

Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer?

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

BACKGROUND Docetaxel is a very active drug against breast cancer, but at the standard dose causes severe myelosuppression. In order to reduce the toxicity while maintaining the activity, weekly docetaxel administration was tested. METHODS We enrolled 30 patients with metastatic breast cancer, who

[Everolimus plus Exemestane in Postmenopausal Metastatic Breast Cancer Patients].

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

The purpose of our study was to test the efficacy and toxicity of everolimus plus exemestane therapy for breast cancer. Between 2014 and 2015, 20 patients diagnosed with breast carcinoma were selected for this retrospective study. Patients received everolimus plus exemestane. As a result, 4 patients

[Everolimus plus exemestane in postmenopausal patients with estrogen-receptor-positive advanced breast cancer - Japanese subgroup analysis of BOLERO -2].

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

In a phase 3, double-blind, randomized, international study (the BOLERO-2), the addition of mTOR inhibitor everolimus to exemestane was evaluated in postmenopausal women with estrogen-receptor-positive (ER⁺) advanced/recurrent breast cancer that was refractory to any nonsteroidal aromatase inhibitor

Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Pathological complete response (pCR) is rare in hormone receptor-positive (HR+) HER2-negative breast cancer (BC) treated with either endocrine therapy (ET) or chemotherapy. Radical resection of locoregional relapse, although potentially curative in some cases, is challenging when the

Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Within an ongoing multicentre phase 3 randomised trial (ELDA, cancertrials.gov ID: NCT00331097), early breast cancer patients, 65-79 years old, with average to high risk of recurrence, are randomly assigned to receive CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, fluorouracil 600 mg/m2,

[A case of recurrent breast cancer successfully treated with docetaxel].

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

A 53-year-old female underwent mastectomy for left breast cancer in April, 1993. She was given oral tamoxifen but this had to be discontinued due to its side effects. In March, 1998, she developed bone and lung metastases, in spite of treatment with combination chemotherapy (CEF). We thus treated

Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Background and objectives: Chemotherapy does not only affect cancer cells; it also affects, to a greater or lesser degree, all other cells in the body. This toxicity should be assessed according to its severity, frequency, and duration,

An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

BACKGROUND Sunitinib has shown single-agent activity in patients with previously treated metastatic breast cancer (MBC). We investigated the safety of the combination of sunitinib and paclitaxel in an exploratory study of patients with locally advanced or MBC. METHODS Patients received oral

Oral health-related concerns, behavior, and communication with health care providers of patients with breast cancer: impact of different treatments.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE The objectives are to compare responses of breast cancer (BCa) treatment groups (chemotherapy, tamoxifen, and aromatase inhibitors (AIs) to each other and a control regarding (a) subjective oral health, (b) oral health-related behaviors, (c) oral health-related concerns, and (d)

Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

BACKGROUND We recently reported that self-evaluation of the incidence and severity of treatment-related side effects (TSEs) using a National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0-based questionnaire was feasible and more informative than doctor reports in

Претходна
1
2
Следећи

Придружите се нашој
facebook страници

Herbal & Natural Medicine

Најкомплетнија база лековитог биља подржана науком

Ради на 55 језика
Биљни лекови потпомогнути науком
Препознавање биљака по слици
Интерактивна ГПС мапа - означите биље на локацији (ускоро)
Читајте научне публикације повезане са вашом претрагом
Претражите лековито биље по њиховим ефектима
Организујте своја интересовања и будите у току са истраживањем вести, клиничким испитивањима и патентима

Упишите симптом или болест и прочитајте о биљкама које би могле да помогну, укуцајте неку биљку и погледајте болести и симптоме против којих се користи.
* Све информације се заснивају на објављеним научним истраживањима